Not all clinical research networks are built the same. Sponsors and CROs evaluating site networks — and patients looking for access to cutting-edge treatments — need to understand what separates a high-performing network from an average one. This article breaks down the criteria that define the top clinical research site networks in the US, and where FOMAT stands against each one.
What is a clinical research site network?
A clinical research site network is a group of clinical trial sites that operate under a shared infrastructure, quality standards, and management model. Rather than working with individual, disconnected sites, sponsors and CROs partner with networks to run multi-site studies with consistent execution, faster activation, and broader patient access.
The United States is home to dozens of site networks — from large hospital-based systems to community-embedded organizations. The best ones share a set of measurable characteristics that determine their value to sponsors, CROs, patients, and the broader research ecosystem.
The 6 criteria that define a top clinical research network
1. Patient reach and diversity
The primary bottleneck in most clinical trials is patient recruitment. A top network must have direct, proven access to large and diverse patient populations — not just a list of sites, but active relationships with the communities those sites serve.
Diversity in enrollment is not just an ethical imperative. It is a regulatory and scientific requirement. The FDA‘s 2020 guidance on diversity in clinical trials and subsequent legislation have made diverse enrollment a measurable deliverable for sponsors.
What to look for: Percentage of diverse enrollment across all studies, recruitment driven by community partnerships rather than paid advertising, multilingual outreach capabilities, and EMR-based pre-screening at scale.
FOMAT’s community-embedded model is built around this principle — with bilingual teams, physician-led referrals, and deep roots in underserved communities across the United States.
2. Site activation speed
Time from award to first patient enrolled is one of the most closely watched metrics in clinical operations. Every day of delay costs sponsors money and can affect competitive timelines for drug development.
Top networks have standardized start-up playbooks, pre-qualified investigators, and infrastructure already in place — so activation is a process, not a scramble.
What to look for: Average days from award to site activation, whether the network has a documented start-up playbook, and whether regulatory and contract templates are already in place.
FOMAT’s embedded model means research staff and systems are already operating inside partner practices before a study begins — enabling some of the fastest site activation timelines in the industry.
3. Quality control and data integrity
Regulatory agencies and sponsors require that data generated at clinical sites meet strict GCP (Good Clinical Practice) standards. A network that produces unreliable data — regardless of how fast it enrolls — creates downstream problems that can delay or derail a drug program.
Top networks have built-in quality oversight at every stage, not just at the end of a study.
What to look for: Whether the network uses eSource, eConsent, and eRegulatory systems; whether QC review happens continuously or only at study closeout; and retention rates as a proxy for participant experience and site quality.
FOMAT sites are eSource, eConsent, eRegulatory, and remote monitoring ready, with continuous quality oversight built into every study from activation through closeout.
4. Therapeutic area depth
A network that conducts trials across many therapeutic areas without genuine expertise in any of them is not a strong partner. The best networks have accumulated protocol experience, trained investigators, and enrolled patient populations in specific disease areas — and that depth shows in their enrollment and retention numbers.
What to look for: Number of completed studies per therapeutic area, whether the network has dedicated investigators with subspecialty training, and whether they have existing patient registries or EMR cohorts in the relevant indication.
FOMAT has active experience across cardiovascular and circulatory diseases, digestive diseases and gastroenterology, endocrinology and metabolic disorders, infectious diseases and vaccines, nephrology, neurology, oncology, ophthalmology and retina, pediatrics and adolescents, rheumatology, and urology.
5. Geographic coverage and access to underserved communities
A clinical trial that only enrolls patients from major metropolitan areas produces data that does not reflect the broader US population. Top networks have meaningful presence in community settings — not just academic medical centers.
What to look for: Number of active sites, distribution across states and community types, and whether the network actively serves Hispanic, Black, and other underrepresented communities.
FOMAT operates 40+ active clinical research sites across the United States, with a strong presence in California’s Central Coast and Central Valley — regions with large Hispanic and underserved populations — and additional sites in Colorado, New Mexico, Virginia, Michigan, and Maryland.
6. Embedded vs. standalone model
Traditional standalone research sites operate separately from the patient’s regular care team. This creates friction: patients have to travel to unfamiliar facilities, their regular doctors are not involved, and the research feels disconnected from their healthcare.
The embedded model — where research is integrated directly into existing medical practices — removes that friction. Patients participate in studies alongside their regular care, physicians they already trust introduce them to trials, and enrollment barriers drop significantly.
What to look for: Whether the network places research staff inside existing practices, whether physicians at partner sites are active co-investigators, and whether the network has data showing the enrollment impact of its model.
FOMAT is an Embedded Research Organization (ERO) — one of the few in the US operating fully under this model. Research staff are based inside partner medical practices, and central teams handle contracts, budgets, regulatory, and finance across the entire network.
What patients should look for in a clinical research network
For patients considering joining a clinical trial, the right network makes the experience safe, respectful, and accessible. Key factors:
- No cost to participate. Study-related visits, tests, and investigational medication are covered. You do not need health insurance.
- Bilingual support. You should be able to ask questions and receive information in your preferred language.
- Your regular doctor stays involved. In most studies, your regular physician can continue your care while you participate.
- Voluntary participation. You can leave a study at any time, for any reason, without penalty.
- Compensation for your time. Participants are compensated for their time and travel.
FOMAT meets all of these criteria across its network. To find an active study near you, visit fomatmedical.com/patient-active-studies.
Frequently asked questions
What is the largest clinical research site network in the United States?
Several large networks operate across the US, including academic medical center consortia, hospital networks, and independent site organizations. Among community-embedded networks focused on diversity, FOMAT operates one of the largest and most active networks in the western United States, with 40+ sites and a growing presence nationally.
What is an Embedded Research Organization (ERO)?
An ERO integrates clinical research directly into existing healthcare settings — physician practices, clinics, and health systems — rather than operating as a standalone research facility. This model improves patient recruitment, reduces barriers to participation, and delivers more consistent trial execution. FOMAT is one of the few organizations in the US operating fully under this model.
How do sponsors select a clinical research site network?
Sponsors and CROs evaluate networks based on therapeutic area experience, site activation speed, patient recruitment track record, diversity enrollment rates, quality systems, and geographic coverage. FOMAT’s business development team can provide feasibility assessments and site-specific metrics for any therapeutic area.
How do I join a clinical trial through FOMAT?
Browse open studies at fomatmedical.com/patient-active-studies or contact the trials information team at (805) 465-3574 or [email protected].
Does FOMAT work with international sponsors and CROs?
Yes. FOMAT works with US-based and international sponsors and CROs conducting trials in the United States. Contact the business development team at [email protected] or (805) 483-1185.